REGN Operating Income Growth
Regeneron Pharmaceuticals · Operating Income Growth
REGN Operating Income Growth
Year-over-year change vs the same period a year earlier
Latest reported3.36%period ending
REGN TTM Operating Income YoY % (-87.88% → 3.36%)
Year-over-year change
High-resolution chart · PNG
REGN operating income growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | Operating Income Growth |
|---|---|
| 3.3638% | |
| -5.2702% | |
| -10.344% | |
| -8.9603% | |
| -5.9226% | |
| -4.9285% | |
| -6.7811% | |
| -10.8784% | |
| -10.4357% | |
| -16.8949% | |
| -16.592% | |
| -29.5993% | |
| -35.6195% | |
| -46.8374% | |
| -42.632% | |
| -13.6097% | |
| 5.994% | |
| 128.6348% | |
| 150.1482% | |
| 142.2487% | |
| 141.0943% | |
| 64.1714% | |
| 61.8518% | |
| 36.9905% | |
| 29.4343% | |
| -0.7074% | |
| -12.8092% | |
| -4.3714% | |
| -6.4477% | |
| 10.4198% | |
| 21.8721% | |
| 24.7576% | |
| 35.3411% | |
| 54.7709% | |
| 56.2732% | |
| 55.3961% | |
| 35.857% | |
| 10.3496% | |
| 6.2963% | |
| -4.2092% | |
| 16.9319% | |
| 36.9611% | |
| 46.3403% | |
| 54.623% | |
| 22.5342% | |
| 18.6508% | |
| 12.5594% | |
| 18.2467% | |
| 31.7573% | |
| 35.034% | |
| 65.0394% | |
| 157.4311% | |
| 7,547.181% | |
| 516.5196% | |
| 324.4664% | |
| 280.3693% | |
| 107.007% | |
| -64.2777% | |
| -176.8565% | |
| -20.582% | |
| -32.163% | |
| -0.9355% | |
| 0% | |
| -78.7817% | |
| -5.8544% | |
| 6.2035% | |
| 17.7182% | |
| -3.4316% | |
| -2.5697% | |
| 5.6133% | |
| 21.3134% | |
| 50.8856% | |
| 31.9574% | |
| 19.1615% | |
| -6.3155% | |
| -34.4127% | |
| -17.0825% | |
| -3.5575% | |
| 11.9084% | |
| -11.6179% | |
| -63.0204% | |
| -148.5179% | |
| -2,264.5058% | |
| -209.9582% | |
| -199.3229% | |
| -189.1036% | |
| 535.8547% | |
| 361.1987% | |
| 283.3011% | |
| 100% | |
| 67.9966% | |
| 49.5089% | |
| 26.1277% | |
| 9.8795% | |
| 9.6372% | |
| 12.8009% | |
| 11.6082% | |
| 24.923% | |
| -129.7804% | |
| -218.2083% |